{"id":"NCT03347422","sponsor":"Bioverativ, a Sanofi company","briefTitle":"A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Without A Recent History of Blood Transfusion","officialTitle":"A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Without a Recent History of Blood Transfusion","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-03-17","primaryCompletion":"2021-12-03","completion":"2021-12-03","firstPosted":"2017-11-20","resultsPosted":"2022-12-23","lastUpdate":"2022-12-23"},"enrollment":42,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Cold Agglutinin Disease"],"interventions":[{"type":"DRUG","name":"sutimlimab (BIVV009)","otherNames":[]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[{"label":"BIVV009/BIVV009","type":"EXPERIMENTAL"},{"label":"Placebo/BIVV009","type":"EXPERIMENTAL"}],"summary":"The purpose of Part A was to determine whether sutimlimab administration resulted in a greater than or equal to (\\>=)1.5 grams per deciliter (g/dL) increase in hemoglobin (Hgb) level and avoidance of transfusion in participants with primary cold agglutinin disease (CAD) without a recent history of blood transfusion. The purpose of Part B was to evaluate the long-term safety and tolerability of sutimlimab in participants with primary CAD.","primaryOutcome":{"measure":"Part A: Percentage of Participants With Response to Treatment","timeFrame":"From Week 5 through Week 26","effectByArm":[{"arm":"BIVV009","deltaMin":72.7,"sd":null},{"arm":"Placebo","deltaMin":15,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":7},"locations":{"siteCount":53,"countries":["United States","Australia","Austria","Belgium","Canada","France","Germany","Israel","Italy","Japan","Netherlands","Norway","Spain","United Kingdom"]},"refs":{"pmids":["36403132","35687757"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":17},"commonTop":["Fatigue","Anaemia","Arthralgia","Hypertension","Headache"]}}